Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$611.1MBeat by $268.2M
EPS$2.02Beat by $0.91
Revenue estimate$342.9M
EPS estimate$1.11

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$354.7M
EPS estimate$0.17

Financials

Q2 2025

Income statement

See full
Revenue$611.1M+68.4%
Operating income$115.6M—
Net income$196.9M+2,948%
EPS (diluted)$1.89—

Balance sheet

See full
Cash & equivalents$510.6M+33.1%
Total debt$214.4M-8.8%
Total equity$1.4B+30.4%
Total assets$3.7B+7.5%

Cash flow

See full
CapEx$31.8M+9.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.87B-87.4%
Enterprise value$1.57B-89.3%

Returns & leverage

See full
Return on equity-4.7%-4.9pp
Debt / equity0.2×-0.1×
Current ratio2.9×-1.0×

Segments

By product

See full
Elevidys$281.9M—
Pmo Products$231.3M—

By segment

See full
All Other Segments$611.1M+68.4%

FAQ

When did Sarepta Therapeutics, Inc. report Q2 2025 earnings?
Sarepta Therapeutics, Inc. (SRPT) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Sarepta Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Sarepta Therapeutics, Inc. reported revenue of $611.1M and eps of $2.02 for Q2 2025.
Did Sarepta Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $342.9M by $268.2M. EPS beat the consensus estimate of $1.11 by $0.91.
How did Sarepta Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 68.4% from $362.9M a year earlier and eps grew 2785.7% from $0.07.
Where can I find Sarepta Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-103971) directly on SEC EDGAR. The filing index links above go to sec.gov.